Loading...

KLRS KALARIS THERAPEUTICS INC Management Changes 8-K Filing

KLRS

KLRS

KALARIS THERAPEUTICS INC

(KLRS)

2026 8-K

Management Change

Financial Results Update

Corporate Presentation Update

Securities Purchase Agreement

Clinical Trial Results

Financial Results Announced

Management Change

Annual Meeting Results

Financial Results Report

Financial Statements

Management Changes

Board Appointment

Merger Completion

Merger Announcement

Stock Split Announcement

Stock Split Announcement

Stock Split Approval

Merger Agreement

Termination of Lease Agreement

Termination of Sublease Agr...

Annual Meeting of Stockholders

Management Bonuses Approved

Workforce Reduction and Res...

Financial Results Announcement

Financial Results Announcement

Public Offering

Termination of Prospectus S...

Amendment to Certificate of...

Earnings Report

Appointment of Director

Financial Results and Posit...

Earnings Reports

External Links:

On April 8, 2026, Kalaris Therapeutics, Inc. reported the resignation of Chief Financial Officer Matthew Gall, effective April 14, 2026, with Brett Hagen succeeding him as principal financial officer. This filing is considered significant from an equity investor's perspective due to the change in key management.

AI Assistant

KALARIS THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.